University of Pennsylvania
Welcome,         Profile    Billing    Logout  
 14 Trials 
22 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Merkel, Peter A
NCT02108860 / 2013-005535-24: Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)

Completed
3
65
Europe, Canada, US
Abatacept, CTLA4-Ig, Orencia, placebo
University of South Florida, The Cleveland Clinic, Bristol-Myers Squibb, University of Pennsylvania, National Institutes of Health (NIH), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Granulomatosis With Polyangiitis (Wegener's), Granulomatosis With Polyangiitis, Wegener's Granulomatosis, ANCA-Associated Vasculitis
07/23
12/23
NCT01933724: The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach

Active, not recruiting
3
12
US
5 mg prednisone, 5 mg glucocorticoids, 5 mg/day prednisone, 0 mg prednisone, no prednisone, no glucocorticoids
University of South Florida, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Office of Rare Diseases (ORD), National Center for Advancing Translational Sciences (NCATS), Rare Diseases Clinical Research Network
Granulomatosis With Polyangiitis, Wegener Granulomatosis, Vasculitis
12/25
12/25
NCT01940094: The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach

Completed
3
159
Canada, US
5 mg Prednisone, •5 mg/day glucocorticoids, •5 mg/day prednisone, •5 mg/day steroids, 0 mg Prednisone
University of Pennsylvania, National Heart, Lung, and Blood Institute (NHLBI), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Office of Rare Diseases (ORD), National Center for Advancing Translational Sciences (NCATS), Rare Diseases Clinical Research Network
Granulomatosis With Polyangiitis
12/24
12/24
OCEAN, NCT05263934 / 2021-005726-15: Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

Recruiting
3
160
Europe, Canada, Japan, US, RoW
Depemokimab, Mepolizumab, Placebo matching mepolizumab, Placebo matching depemokimab
GlaxoSmithKline
Eosinophilic Granulomatosis With Polyangiitis
10/25
11/25
ABAGART, NCT04474847: Abatacept for the Treatment of Giant Cell Arteritis

Recruiting
3
78
Canada, US
Abatacept, CTLA4-Ig, Orencia, Placebo
University of Pennsylvania
Giant Cell Arteritis
12/29
12/29
LoDoNaVasc, NCT03482479: Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis

Recruiting
2
36
Canada, US
Naltrexone Hydrochloride, Placebo Comparator
University of Pennsylvania
Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS), Giant Cell Arteritis, Granulomatosis With Polyangiitis, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu Arteritis
12/24
12/24
NCT05376319: PR3-AAV Resilient Remission or PRRR

Terminated
2
6
US
Obinutuzumab, Rituximab
Mayo Clinic, Genentech, Inc.
Granulomatosis With Polyangiitis, Microscopic Polyangiitis, ANCA Associated Vasculitis
05/24
05/24
NCT04919538: Longitudinal Study for Relapsing Polychondritis

Recruiting
N/A
100
US
University of Pennsylvania
Relapsing Polychondritis, Vasculitis
01/26
01/26
NCT00315380: Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis

Recruiting
N/A
700
Canada, US
University of Pennsylvania, GlaxoSmithKline, AstraZeneca
Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
12/28
12/28
V-PREG, NCT02593565: Vasculitis Pregnancy Registry

Recruiting
N/A
100
US
Online questionnaires
University of Pennsylvania, Duke University, University of South Florida
Vasculitis, Behcet's Disease, CNS Vasculitis, Cryoglobulinemic Vasculitis, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS), Granulomatosis With Polyangiitis (GPA), Wegener's Granulomatosis, IgA Vasculitis, Henoch-Schoenlein Purpura (HSP), Microscopic Polyangiitis (MPA), Polyarteritis Nodosa (PAN), Takayasu Arteritis (TAK), Urticarial Vasculitis, Systemic Vasculitis
12/25
12/26
NCT02967068: VCRC Tissue Repository

Recruiting
N/A
1000
Canada, US
University of Pennsylvania, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Advancing Translational Sciences (NCATS), Office of Rare Diseases (ORD)
Aortitis, Cutaneous Vasculitis, Eosinophilic Granulomatosis With Polyangiitis, Giant Cell Arteritis, Granulomatosis With Polyangiitis (Wegener's), Henoch-Schonlein Purpura, IgA Vasculitis, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu Arteritis, Churg-Strauss Syndrome
12/25
12/25
NCT05734404: Longitudinal Study for Central Nervous System Vasculitis

Recruiting
N/A
40
Canada, US
University of Pennsylvania, The Cleveland Clinic
Central Nervous System Vasculitis, CNS Vasculitis, CNSV, Vasculitis
12/26
12/26
NCT01241305: One-Time DNA Study for Vasculitis

Recruiting
N/A
1000
Canada, US, RoW
University of Pennsylvania, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Office of Rare Diseases (ORD), Rare Diseases Clinical Research Network
Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Giant Cell Arteritis, Granulomatosis With Polyangiitis (Wegener's), Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu's Arteritis
08/27
08/27
Aggarwal, Charu
AVANZAR, NCT05687266 / 2021-004606-21: Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

Active, not recruiting
3
1350
Europe, Canada, Japan, US, RoW
Datopotamab deruxtecan, Dato-DXd, Durvalumab, MEDI4736, Imfinzi, Carboplatin, Pembrolizumab, Cisplatin, Pemetrexed, Paclitaxel
AstraZeneca, AstraZeneca AB
NSCLC
11/27
11/27
EA5163, NCT03793179: Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

Active, not recruiting
3
600
Canada, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, QL2107, RPH 075, RPH-075, RPH075, SCH 900475, SCH-900475, SCH900475, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI)
Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
09/27
09/27
NCT04735068: Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

Active, not recruiting
2
11
US
Binimetinib Pill, Hydroxychloroquine Pill
Abramson Cancer Center at Penn Medicine, Pfizer
Non-Small Cell Lung Cancer, KRAS Mutation-Related Tumors
08/22
12/23
LuTK02, NCT04495153: CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC

Active, not recruiting
2
90
US
Aglatimagene besadenovec, CAN-2409, AdV-tk
Candel Therapeutics, Inc., NYU Langone Health
Non Small Cell Lung Cancer
12/24
12/26
ALKOVE-1, NCT05384626 / 2022-000122-21: A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation

Recruiting
1/2
470
Europe, Canada, Japan, US, RoW
NVL-655
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
02/26
03/26
EGRET, NCT05647122: First in Human Study of AZD9592 in Solid Tumors

Recruiting
1
228
Europe, Canada, Japan, US, RoW
AZD9592, Osimertinib, 5-Fluorouracil (5-FU), Leucovorin, Bevacizumab
AstraZeneca
Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
12/25
12/25
NCT04659135: ASCO Survey on COVID-19 in Oncology (ASCO) Registry

Active, not recruiting
N/A
7000
US
American Society of Clinical Oncology
Neoplasms, Coronavirus
08/24
01/25
TESTING, NCT05790460: Telehealth Based Synchronous Navigation to Improve Molecularly-Informed Care for Patients With Lung Cancer

Terminated
N/A
55
US
Telehealth
Abramson Cancer Center at Penn Medicine, National Cancer Institute (NCI)
Non-small Cell Lung Cancer
01/24
04/24
iNUDGE, NCT05853887: Liquid Biopsy Based NGS in Newly Diagnosed NSCLC

Recruiting
N/A
360
US
iNUDGE
Charu Aggarwal, Loxo Oncology, Inc.
Non Small Cell Lung Cancer Metastatic, Newly Diagnosed NSCLC, Non-Squamous Non-Small Cell Neoplasm of Lung
06/25
12/25

Download Options